PROVIREX Genome Editing Therapies GmbH is a pioneering biotech company building the world’s first genome editing therapy to functionally cure HIV.

Current antiretroviral therapies suppress HIV replication but leave integrated proviral DNA intact. PROVIREX addresses this unmet medical need directly. Our proprietary Brec1 recombinase platform excises integrated HIV DNA from infected cells with a level of accuracy and safety no other approach matches.

We are now advancing into clinical development, preparing a first-in-human trial with leading university medical centers across Germany — backed by Europe’s only S3** biosafety cleanrooms for ATMP manufacturing in Hamburg.

Founded in 2019, we are driven by one mission: a definitive, lifelong cure for people living with HIV (PLWH).